Climb Bio Statistics
Total Valuation
Climb Bio has a market cap or net worth of $285.68 million. The enterprise value is $62.64 million.
| Market Cap | 285.68M |
| Enterprise Value | 62.64M |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Climb Bio has 67.06 million shares outstanding. The number of shares has increased by 6.18% in one year.
| Shares Outstanding | 67.06M |
| Shares Change (YoY) | +6.18% |
| Shares Change (QoQ) | +9.81% |
| Owned by Insiders (%) | 0.73% |
| Owned by Institutions (%) | 27.24% |
| Float | 26.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.28 |
| P/FCF Ratio | 5,011.86 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 1,098.88 |
Financial Position
The company has a current ratio of 60.41, with a Debt / Equity ratio of 0.00.
| Current Ratio | 60.41 |
| Quick Ratio | 59.65 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | 1.75 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -38.35% and return on invested capital (ROIC) is -25.04%.
| Return on Equity (ROE) | -38.35% |
| Return on Assets (ROA) | -24.54% |
| Return on Capital (ROIC) | -25.04% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$5.84M |
| Employee Count | 11 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +66.41% in the last 52 weeks. The beta is -0.38, so Climb Bio's price volatility has been lower than the market average.
| Beta (5Y) | -0.38 |
| 52-Week Price Change | +66.41% |
| 50-Day Moving Average | 6.17 |
| 200-Day Moving Average | 5.58 |
| Relative Strength Index (RSI) | 27.33 |
| Average Volume (20 Days) | 412,353 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -67.21M |
| Pretax Income | n/a |
| Net Income | -64.20M |
| EBITDA | n/a |
| EBIT | -67.21M |
| Earnings Per Share (EPS) | -$2.28 |
Balance Sheet
The company has $223.14 million in cash and $100,000 in debt, giving a net cash position of $223.04 million or $3.33 per share.
| Cash & Cash Equivalents | 223.14M |
| Total Debt | 100,000 |
| Net Cash | 223.04M |
| Net Cash Per Share | $3.33 |
| Equity (Book Value) | 222.28M |
| Book Value Per Share | 3.33 |
| Working Capital | 222.26M |
Cash Flow
| Operating Cash Flow | 57,000 |
| Capital Expenditures | n/a |
| Free Cash Flow | 57,000 |
| FCF Per Share | $0.00 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Climb Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.18% |
| Shareholder Yield | -6.18% |
| Earnings Yield | -22.47% |
| FCF Yield | 0.02% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |